NewsRoom Articles - Page 41 of 154 - PsychedelicNewsWire (PNW)

ThursdayJan 12, 2023 9:00 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis

Silo Pharma recently provided an update on an ongoing study delving into the potential use of SPU-21 joint homing peptides as an alternative treatment for rheumatoid arthritis The study, which is being carried out in conjunction with the University of Maryland, Baltimore, has resulted in positive initial results Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions to address a variety of underserved medical conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently revealed the positive interim data from its dose optimization…

WednesdayJan 11, 2023 10:38 am

Second MAPS Phase 3 Clinical Trial Confirms Positive MDMA Results

A growing body of research has revealed that psychedelic drugs such as psilocybin and MDMA have the potential to alleviate a variety of mental illnesses. Decades of federal prohibition made it nigh impossible for scientists to research the possible medical applications of psychedelics, but there has been an upsurge in psychedelic research over the past couple of years. Early results have been extremely encouraging, with clinical studies finding that psychedelics can cause profound changes in mental health and perception when paired with psychotherapy. The Multidisciplinary Association For Psychedelic Studies (MAPS) is at the helm of the first-ever phase 3 clinical…

TuesdayJan 10, 2023 1:33 pm

Ketamine, Smiling Faces Combo Hold Promise in Treating Depression

Early research and clinical trials have revealed that psychedelics can have significant mental health benefits when paired with psychotherapy. Researchers have found that hallucinogenic drugs such as ketamine and psilocybin can be effective against severe mental illnesses, including post-traumatic stress disorder, depression and eating disorders. Furthermore, psychedelic drugs deliver these benefits without the side effects that are often seen in pharmaceutical medications. Given that the field of psychedelic research is largely in its infancy, researchers across the world are still studying psychedelic drugs and trying to figure out how to implement them in mental health therapies. A recently published study…

MondayJan 09, 2023 11:12 am

BMI Doesn’t Impact Intensity of Psychedelic Experiences

New research has found that the intensity of a psilocybin trip doesn’t depend on an individual’s body mass index (BMI). BMI is a measure of body fat based on height and weight that applies to adults. Psilocybin is the primary psychoactive compound found in hallucinogenic mushrooms. When ingested, this compound acts as a receptor agonist of 5-HT2A to activate serotonin receptors in the prefrontal cortex in the brain. This decreases the energy required by the brain to alternate between different activity states. A Center for Psychedelic Research research associate, Meg J. Spriggs, the author of the study, stated that the…

FridayJan 06, 2023 11:44 am

Controlled Study Shows Single Modest Psilocybin Dose Cuts Depression Symptoms for a Fortnight

New research has found that one dose of psilocybin administered together with therapy significantly alleviates symptoms of depression. Psilocybin is the primary psychoactive compound found in magic mushrooms. This compound, which alters an individual’s state of consciousness when consumed, has been used for centuries in religious and spiritual rituals. In the last few years, numerous studies on psilocybin have been conducted to determine its potential therapeutic benefits. While promising results have been observed when the substance is used in managing anxiety and depression, more studies are required to fully understand the effectiveness of psilocybin therapy. The latest study, carried out…

ThursdayJan 05, 2023 1:39 pm

New York Legislators File Measure to Legalize Psychedelics

Last week, legislators in New York filed a measure to legalize psychedelics such as ibogaine and psilocybin for the 2023 legislative session. The bill, which will be introduced formally this week, is being sponsored by assembly members Linda Rosenthal, Karines Reyes and Jo Anne Simon. The bill would make the use, possession, cultivation, creation, production, gifting, analysis, sharing or exchange of natural fungus or plant-based hallucinogens legal for individuals aged 21 and above. The psychedelics that will be legalized if the bill is approved include psilocybin, mescaline, psilocyn, ibogaine and DMT. The bill will also allow individuals to use the…

WednesdayJan 04, 2023 11:50 am

Schools Step Up Training for Psychedelic Therapy Professionals

Psychedelic therapies are poised to revolutionize the psychiatric industry. With America’s mental health crisis getting worse by the year, researchers have been casting their attention on psychedelics for their potential mental-health benefits. Initial research into hallucinogenic drugs such as psilocybin and ketamine has revealed that they are capable of alleviating the symptoms of a variety of mental illnesses. As a result, pharmaceutical companies have been injecting millions of dollars into psychedelic research and the development of psychedelic-assisted therapies. Experts predict that the market for psychedelic drugs will grow explosively over the next decade, increasing from around $2 billion in 2020…

TuesdayJan 03, 2023 3:44 pm

Three Trends That May Shape the Psychedelics Industry Next Year

The psychedelics industry has grown significantly these past few years. However, before it can deliver on its potential, the sector will need to achieve various milestones and overcome certain challenges. Below, we look at some of the trends that may shape this burgeoning industry in 2023. Drug approvals Companies such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) and Compass Pathways have been conducting clinical trials on psychedelic drugs for the treatment of a range of conditions. These trials may make or break the psychedelic industry’s viability, which further highlights the huge role they can play in the…

ThursdayDec 29, 2022 12:41 pm

California Senator Refiles Measure to Legalize Psychedelics in 2023

Senator Scott Wiener of California has filed a measure to legalize the possession of a number of psychedelics. This comes after his office announced earlier this week that Wiener would be introducing the revised bill again in 2023. The revised bill will revoke state law that prohibits any mycelium or spores capable of producing mushrooms that contain psilocin or psilocybin. Psilocybin and psilocin are two of the major psychoactive components found in magic mushrooms. The ban on drug paraphernalia imposed on the substances mentioned in the state of California will also be repealed under the revised bill. During a phone…

WednesdayDec 28, 2022 11:49 am

Psychedelic Therapy May Soon Feature in Health Benefits

Every few years, new or previously forgotten discoveries shake up the very foundation of how industries operate. The development of the internet, for instance, altered society in a multitude of ways, enabling previously unknown ways of connecting and thinking and completely revolutionizing how society functions. Psychedelics are poised to transform the psychiatric industry in a similar way. Mental illness has gripped the American populace for decades now, with reports showing that mental health in America has been getting worse for quite a while now. Although pharmaceutical medications can be used to treat mental disorders, they often come with a multitude…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000